Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Dermatology | Rheumatology | Family Medicine
Disease Category: Psoriasis and Psoriatic Disorders
Location: United States, NY

Clinical Trial Details

Overview

Research Study Summary

Psoriasis Inflammation and Systemic Co-morbidities: Is it Preventable or Reversible?

Purpose

Psoriasis is a chronic relapsing prevalent inflammatory disease affecting 2-4% of the world's population. Severe psoriasis is a disabling disease affecting the physical and emotional well being of patients, and its effect on quality of life is similar to that seen with other major medical diseases such as diabetes, rheumatoid arthritis, and cancer. Lately, it is increasingly being recognized that psoriasis is not merely a skin disease but is probably associated with other co-morbidities such as psoriatic arthritis, Crohn's disease, the metabolic syndrome and cardiovascular diseases (CVD). The metabolic syndrome is a combination of diabetes mellitus type II (or insulin resistance), hypertension, central obesity, and combined hyperlipidemia (elevated LDL; decreased HDL; elevated triglycerides). As the literature linking psoriasis and the metabolic syndrome expands, also reports of an increased rate of CVD mortality in psoriasis patients accumulates. These data emphasize that metabolic dysregulations are the leading risk factors for occlusive vascular events and early death in patients with severe psoriasis. Progress in understanding the pathogenesis of these apparently diverse diseases has discovered that low-grade systemic inflammation might be the common physiological pathway that may provide the biological plausibility of the associations discovered in the epidemiological studies. Since some of these co-morbidities often become clinically apparent years after the onset of psoriasis we assume that controlling systemic inflammation might prevent or reverse some of these co-morbidities.

Presently there is no study in psoriasis that shows that a "systemic" co-morbidity can be prevented or treated by reversing skin inflammation.

Patient Inclusion Criteria:

  • Age > 18years
  • Plaque-type psoriasis
  • Psoriasis on over 10% of the body
  • Non-smoker

Patient Exclusion Criteria:

  • Diabetic
  • HIV +
  • Hepatitis C or B
  • Currently taking a statin
  • Heart attack, stroke or heart surgery
  • Taking more than one medication for hypertension
  • Previously tested positive for PPD
  • Women who are pregnant or nursing

To Learn more
Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Clinical Research Support Office
The Rockefeller University Hospital
1230 York Avenue
New York, NY 10065
Phone: 1.800.RU.CARES (800.782.2737)

View Map

Research Center Information: The Rockefeller University Hospital

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 166569

Date Last Changed: July 23, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.